SK's "M-vix", an erectile dysfunction therapy, to market in Korea.

Published: 2007-07-23 06:58:00

Updated: 2007-07-23 06:58:00

Following a serial market launching of the drugs for erectile dysfunction therapy by Pfizer, Lilly, Bayer, Dong-A and CKD, SK Chemical seems to enter this annual 80 billion won of markets (as of 2006) very soon.

The KFDA approval for "M-vix 50 and 100mg (mirodenafil)" was completed on July 18...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK